AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34126939
Drug: ETV (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ETV (0.5 mg/d)
Trial: 34129158
Drug: Adipose tissue-derived
RxNorm normalized name: human adipose preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adipose tissue-derived mesenchymal stem/stromal cells (ADSC) infusion at a dosage of 1 million cells/kg of body weight via intravenous route.
Trial: 34129808
Drug: Corticosteroid treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid treatment, specific dosage and duration not available
Trial: 34722661
Drug: Control group,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group, specific treatment not available
Trial: 34130554
Drug: Solution-Focused Brief
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Solution-Focused Brief Therapy
Trial: 34130709
Drug: Oral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutritional supplements (ONS) with nutritional counseling
Trial: 34130731
Drug: Early combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early combination (EC) therapy
Trial: 34130731
Drug: Metformin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin monotherapy (MET)
Trial: 34131041
Drug: Olaparib in
RxNorm normalized name: Product containing olaparib in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib in combination with weekly carboplatin plus paclitaxel
Trial: 34131423
Drug: TAK-003 (tetravalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-003 (tetravalent dengue vaccine)
Trial: 34131821
Drug: HIPEC with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIPEC with gemcitabine administered at 1000 mg/m²
Trial: 34132071
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of high-dose selenium (2,000 μg/day)
Trial: 34132642
Drug: Directly Observed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Directly Observed Therapy (DOT) via mobile health application carried out by community workers.
Trial: 34133209
Drug: Germline genotype-directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Germline genotype-directed therapy
Trial: 34134507
Drug: Hypotension during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypotension during endovascular therapy in patients with no PComA
Trial: 34134507
Drug: Hypotension during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypotension during endovascular therapy in patients with PComA
Trial: 34134830
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBGT)
Trial: 34134832
Drug: Memory Support
RxNorm normalized name: Brainstrong Memory Support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memory Support Treatment Provider Checklist
Trial: 34135022
Drug: Net endogenous
RxNorm normalized name: [(im-Bzl)-D-His6,Pro9-NEt]-gonadotropin releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Net endogenous acid production using urinary excretion
Trial: 34135566
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection guide (IIG)
Trial: 34135843
Drug: Repeated Mesenchymal
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated Mesenchymal Stem Cell Injections
Trial: 34136501
Drug: Liraglutide, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide, a glucagon-like peptide-1 receptor agonist
Trial: 34136782
Drug: Patiromer at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patiromer at doses ranging from 4.2 to 16.8 g twice daily
Trial: 34136987
Drug: MT-8 h
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MT-8 h and MT-12 h formulations (120 mg)
Trial: 34136987
Drug: MT-12 h
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MT-12 h once-daily for 3 days at three dose levels
Trial: 34136987
Drug: MM-12 h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MM-12 h formulation at two dose levels
Trial: 34136987
Drug: Immediate release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release (IR) formulation (120 mg)
Trial: 34137430
Drug: Vedolizumab 300
RxNorm normalized name: vedolizumab 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vedolizumab 300 mg every 8 weeks
Trial: 34140107
Drug: Triglyceride levels
RxNorm normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triglyceride levels ≥150 mg/dl
Trial: 34140212
Drug: Hydrocortisone replacement
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone replacement and/or stress dosing during illness
Trial: 34140212
Drug: ACTH low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ACTH low-dose stimulation test
Trial: 34140248
Drug: Onalespib plus
RxNorm normalized name: Onalespib
DrugBank: Onalespib (DB06306)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onalespib plus erlotinib (erlotinib 150 mg orally every morning and onalespib 120 mg/m)
Trial: 34140403
Drug: APX005M (0.03,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APX005M (0.03, 0.1, or 0.3 mg/kg i.v.) with cabiralizumab and nivolumab
Trial: 34140403
Drug: APX005M (0.03,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APX005M (0.03, 0.1, or 0.3 mg/kg i.v.) with cabiralizumab without nivolumab
Trial: 34140482
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of osimertinib and dacomitinib
Trial: 34140482
Drug: Optimal dosing
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal dosing schedule for osimertinib and dacomitinib
Trial: 34140638
Drug: CGM097 10-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGM097 10-400 mg 3qw
Trial: 34140638
Drug: CGM097 300-700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGM097 300-700 mg 3qw 2 weeks on/1 week off
Trial: 34142595
Drug: Enhanced daycare
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced daycare of Traditional Chinese Medicine (TCM)
Trial: 34143416
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg eplerenone once daily
Trial: 34143998
Drug: Fexinidazole 1800
RxNorm normalized name: fexinidazole
DrugBank: Fexinidazole (DB12265)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexinidazole 1800 mg once per day on days 1-4, then 1200 mg on days 5-10
Trial: 34145677
Drug: 30-g FMT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30-g FMT
Trial: 34145677
Drug: 60-g FMT
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60-g FMT
Trial: 34145979
Drug: Mobocertinib (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobocertinib (20 mg) with itraconazole (200 mg once daily)
Trial: 34145979
Drug: Mobocertinib (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobocertinib (160 mg) with rifampin (600 mg once daily)
Trial: 34146238
Drug: Insulin-only configuration
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-only configuration of the iLet
Trial: 34146644
Drug: Oral metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral metronidazole treatment for bacterial vaginosis
Trial: 34146644
Drug: Healthy women
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy women (no treatment mentioned)
Trial: 34147313
Drug: Pembrolizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (200 mg, intravenously, every 3 weeks for 3 courses)
Trial: 34149587
Drug: Robotic Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robotic Therapy (RT)
Trial: 34150661
Drug: Temporary ovarian
RxNorm normalized name: Sus scrofa temporal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temporary ovarian suppression with gonadotropin-releasing hormone agonists (GnRHa)
Trial: 34150661
Drug: Hormone-receptor positive
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone-receptor positive breast cancer
Trial: 34150661
Drug: Concerns about
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concerns about chemotherapy-induced premature ovarian insufficiency and/or infertility
Trial: 34150785
Drug: Reduced-intensity conditioning
RxNorm normalized name: ALLANTOIN 1 g in 100 g TOPICAL CREAM [Scar Reducer Intensive Herbal and Nutrient]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced-intensity conditioning regimen with different haploidentical donors (HIDs) including fludarabine (30 mg/m2)
Trial: 34151781
Drug: Acute triiodothyronine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute triiodothyronine administration
Trial: 34152067
Drug: Patient-centred PEP
RxNorm normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient-centred PEP programme with 28-day regimen; PEP availability seven days/week, PEP hotline, out-of-facility medication delivery.
Trial: 34152281
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care plus TB treatment support tools (TB-TSTs)
Trial: 34152585
Drug: Gefapixant 50
RxNorm normalized name: Gefapixant
DrugBank: Gefapixant (DB15097)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Gefapixant 50 mg BID for 14 days
Trial: 34152898
Drug: Autologous leukemic
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous leukemic apoptotic corpse-pulsed dendritic cells (DC) administered at doses of 9 × 10
Trial: 34153013
Drug: Qualitative point-of-care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qualitative point-of-care drug level tests for efavirenz (EFV)
Trial: 34153013
Drug: Qualitative point-of-care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qualitative point-of-care drug level tests for lopinavir (LPV)
Trial: 34153013
Drug: Qualitative point-of-care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qualitative point-of-care drug level tests for dolutegravir (DTG)
Trial: 34153013
Drug: Simulated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simulated treatment cessation for efavirenz (EFV)
Trial: 34153013
Drug: Simulated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simulated treatment cessation for lopinavir (LPV)
Trial: 34153013
Drug: Simulated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simulated treatment cessation for dolutegravir (DTG)
Trial: 34153264
Drug: ChAdOx1 nCoV-19
RxNorm normalized name: ChAdOx1 nCoV-19
DrugBank: AstraZeneca COVID-19 Vaccine (DB15656)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAdOx1 nCoV-19 vaccine (two doses given 4-6 weeks apart)
Trial: 34154504
Drug: Medtronic Extended
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medtronic Extended Infusion Set (EIS)
Trial: 34154504
Drug: Standard 2-
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard 2- to 3-day infusion sets
Trial: 34154614
Drug: Envafolimab 150
RxNorm normalized name: Envafolimab
DrugBank: Envafolimab (DB15769)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Envafolimab 150 mg subcutaneously weekly in a 28-day treatment cycle
Trial: 34155084
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiotherapy (SBRT) with a dose range of 30-50 Gy delivered in 1, 3, or 5 daily fractions to all sites of active metastatic disease.
Trial: 34157616
Drug: Regorafenib (60-93
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regorafenib (60-93 mg/m2) administered orally once daily for 3 weeks on/1 week off; recommended phase 2 dose is 82 mg/m2.
Trial: 34157782
Drug: Palbociclib plus
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib plus endocrine therapy (125 mg daily; 21 days on and 7 days off)
Trial: 34157782
Drug: Palbociclib plus
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib plus endocrine therapy (Duffy null variant)
Trial: 34157782
Drug: Palbociclib plus
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib plus endocrine therapy (wild-type variant)
Trial: 34158124
Drug: Autologous PRP
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous PRP injection
Trial: 34158124
Drug: Steroid/anesthetic injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid/anesthetic injection (standard care)
Trial: 34158124
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection with normal saline
Trial: 34159342
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg molnupiravir
Trial: 34159342
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg molnupiravir
Trial: 34159343
Drug: Subcutaneous REGEN-COV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous REGEN-COV 1200mg
Trial: 34159344
Drug: Subcutaneous REGEN-COV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous REGEN-COV (1200 mg)
Trial: 34159577
Drug: Single intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous anti-pseudomonal antibiotic therapy
Trial: 34159577
Drug: Combination intravenous
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination intravenous anti-pseudomonal antibiotic therapy
Trial: 34160684
Drug: Pembrolizumab in
RxNorm normalized name: pembrolizumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab in combination with modified FOLFOX6
Trial: 34160684
Drug: Modified FOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified FOLFOX6 (reduced dose due to safety concerns)
Trial: 34160752
Drug: Talazoparib 0.75
RxNorm normalized name: talazoparib 0.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talazoparib 0.75 mg once daily
Trial: 34160752
Drug: Talazoparib 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talazoparib 1.0 mg once daily
Trial: 34160752
Drug: Talazoparib (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talazoparib (both doses)
Trial: 34161665
Drug: Berotralstat 150
RxNorm normalized name: berotralstat 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Berotralstat 150 mg once daily
Trial: 34161665
Drug: Berotralstat 110
RxNorm normalized name: berotralstat 110 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Berotralstat 110 mg once daily
Trial: 34162181
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus anticoagulant
Trial: 34162181
Drug: Periods of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periods of thrombocytosis (>600×10^9/L)
Trial: 34162264
Drug: Other CDI
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other CDI therapies
Trial: 34162435
Drug: Weekly pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly pain and fatigue data collection via text messages
Trial: 34163180
Drug: Mepolizumab (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepolizumab (75 mg intravenously or 100 mg subcutaneously)
Trial: 34164709
Drug: Immune checkpoint
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune checkpoint inhibitors (ICI) with corticosteroid treatment
Trial: 34164709
Drug: Immune checkpoint
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune checkpoint inhibitors (ICI) with occurrence of irAE
Trial: 34164713
Drug: Tivantinib (120-360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tivantinib (120-360 mg orally twice daily) + Bevacizumab (10 mg/kg intravenously every 2 weeks)
Trial: 34164713
Drug: Bevacizumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (10 mg/kg intravenously every 2 weeks)
Trial: 34164711
Drug: L-carnitine (LC)
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-carnitine (LC) 5 mM
Trial: 34164711
Drug: Acetyl-L-carnitine (ALC)
RxNorm normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetyl-L-carnitine (ALC) 5 mM
Trial: 34164711
Drug: Propionyl-L-carnitine (PLC)
RxNorm normalized name: glycine propionyl-L-carnitine
DrugBank: Levocarnitine propionate (DB15980)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propionyl-L-carnitine (PLC) 5 mM
Trial: 34164952
Drug: Rituximab (RTX)
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab (RTX) 375 mg/m² intravenous infusions during the initial 6-month remission-induction phase.
Trial: 34164952
Drug: Rituximab (RTX)
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab (RTX) 375 mg/m² intravenous infusions.
Trial: 34166589
Drug: Adjunctive Mood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive Mood Stabilizers
Trial: 34166627
Drug: Savolitinib 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Savolitinib 600 mg (bodyweight ≥50 kg) or 400 mg (bodyweight <50 kg) once daily until disease progression or intolerable toxicity.
Trial: 34166998
Drug: Higher plerixafor
RxNorm normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Higher plerixafor dosing
Trial: 34168015
Drug: sequential α-/β-emitter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sequential α-/β-emitter therapy
Trial: 34168480
Drug: First-generation EGFR-TKIs
RxNorm normalized name: benzethonium chloride / lidocaine hydrochloride Topical Gel [Tecnu First Aid]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-generation EGFR-TKIs combined with chemotherapy
Trial: 34168987
Drug: Pomalidomide (POM)
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pomalidomide (POM) 2.6 mg/m²
Trial: 34169045
Drug: Walnuts, specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walnuts, specific dosage and duration not available
Trial: 34169045
Drug: Long-Chain Polyunsaturated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-Chain Polyunsaturated Fatty Acids, specific dosage and duration not available
Trial: 34169200
Drug: Ravulizumab administered
RxNorm normalized name: ravulizumab
DrugBank: Ravulizumab (DB11580)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ravulizumab administered every 8 weeks
Trial: 34169203
Drug: High-dose PF-06730512
RxNorm normalized name: Influenza, high-dose, quadrivalent, PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose PF-06730512 (intravenous) every 2 weeks for 12 weeks
Trial: 34169203
Drug: Low-dose PF-06730512
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose PF-06730512 (intravenous) every 2 weeks for 12 weeks
Trial: 35410894
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAPT) at discharge
Trial: 34171919
Drug: New P2Y12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New P2Y12 inhibitor regimen
Trial: 34172622
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy (CBT) as adjunctive treatment
Trial: 34173341
Drug: Third-generation EGFR-TKI
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third-generation EGFR-TKI treatment
Trial: 34173811
Drug: Dalcetrapib (cholesterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalcetrapib (cholesterol ester transfer protein inhibitor)
Trial: 34173969
Drug: UVA therapy
RxNorm normalized name: UVA URSI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UVA therapy for 20 min daily for 5 days
Trial: 34174177
Drug: Molecularly specific
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Molecularly specific positron emission tomography imaging agents targeting ACE2
Trial: 34174903
Drug: Diaphragmatic Thickening
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diaphragmatic Thickening Fraction (DTF) measured at baseline and at 1, 4, 12, 24, 48, 72, and 96 hours of NIV treatment.